[Antiplatelet therapy: should it be withdrawn before any invasive procedure?].

K Maeyns, V Legrand, L A Piérard, P Lancellotti
Author Information
  1. K Maeyns: Service de Cardiologie, CHU Sart-Tilman, Liège, Belgique.

Abstract

Antiplatelet therapy is the leading therapy for the primary and secondary prevention for the atherosclerotic arterial disease. The practical question of withdraw alavoiding or continuation of oral antiplatelet agents accurs currently before any invasive procedure. It is important to compare the relative thrombotic vs hemorrhagic risk. For most interventions, it is recommended to continue antiplatelet therapy. It is particularly important in patients who benefited from drug-eluting stents where the thrombotic risk is major.

MeSH Term

Atherosclerosis
Humans
Platelet Aggregation Inhibitors
Postoperative Hemorrhage
Risk Assessment
Thrombosis

Chemicals

Platelet Aggregation Inhibitors

Word Cloud

Created with Highcharts 10.0.0therapyantiplateletinvasiveimportantthromboticriskAntiplateletleadingprimarysecondarypreventionatheroscleroticarterialdiseasepracticalquestionwithdrawalavoidingcontinuationoralagentsaccurscurrentlyprocedurecomparerelativevshemorrhagicinterventionsrecommendedcontinueparticularlypatientsbenefiteddrug-elutingstentsmajor[Antiplatelettherapy:withdrawnprocedure?]

Similar Articles

Cited By